Current studies have, overall, identified RUNX3 as the dominant member in controlling NK- and CD8+ CTL-mediated antitumor immune responses, but whether RUNX3 is also implicated in controlling the functions of tumor-associated ILCs and myeloid cells is obscure. This evidence concerns the gene RUNX3 and neoplasm.